Q4 2021 Targovax ASA Earnings Presentation Transcript
Welcome to Targovax and our fourth quarter and full year 2021 presentation. My name is Erik Digman Wiklund and I am the CEO of Targovax.
So first, let me give you a brief overview of the main highlights of last year. By far, the most important event of the year was the clinical data that we delivered on ONCOS-102, our lead clinical stage program. We showed a class-leading ORR of 35% in PD-1 refractory melanoma, and we could associate this ORR to deep and durable immune responses in the tumors.
Second, we also showed a very solid median survival of 25 months in frontline mesothelioma in combination with chemotherapy. And this puts ONCOS-102 as the compound with the best survival data that we have seen in mesothelioma. And these 2 data points were
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
